We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$899M
AUM Growth
+$163M
Cap. Flow
+$26.4M
Cap. Flow %
2.93%
Top 10 Hldgs %
55.22%
Holding
69
New
9
Increased
12
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$23M
2
IBB icon
iShares Biotechnology ETF
IBB
+$16.5M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.1M
4
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$6.7M
5
AGN
Allergan Inc
AGN
+$6.6M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$16.4M
2
PBYI icon
Puma Biotechnology
PBYI
+$13.6M
3
IMGN
Immunogen Inc
IMGN
+$6.53M
4
MDVN
MEDIVATION, INC.
MDVN
+$6.52M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 84.05%
2 Financials 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
26
Verastem
VSTM
$536M
$11M 1.22%
73,743
– –
QCOR
27
DELISTED
QUESTCOR PHARMA INC
QCOR
$9.41M 1.05%
162,328
-11,600
-7% -$689K
IRWD icon
28
Ironwood Pharmaceuticals
IRWD
$614M
$9.1M 1.01%
917,052
– –
AMRN
29
Amarin Corp
AMRN
$298M
$8.8M 0.98%
69,586
+1,471
+2% +$176K
ILMN icon
30
Illumina
ILMN
$31B
$8.39M 0.93%
106,749
– –
ARIA
31
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$7.6M 0.85%
412,965
– –
MCK icon
32
McKesson
MCK
$101B
$7.29M 0.81%
56,862
– –
IPXL
33
DELISTED
Impax Laboratories, Inc.
IPXL
$7.07M 0.79%
344,683
– –
ALKS icon
34
Alkermes
ALKS
$8.39B
$6.55M 0.73%
194,870
– –
NBIX icon
35
Neurocrine Biosciences
NBIX
$18.7B
$6.46M 0.72%
570,387
-137,603
-19% -$1.89M
FRX
36
DELISTED
FOREST LABORATORIES INC
FRX
$6.27M 0.7%
146,500
– –
INFI
37
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$6.11M 0.68%
+349,899
New +$6.7M
UNH icon
38
UnitedHealth
UNH
$383B
$5.9M 0.66%
82,436
– –
ENDP
39
DELISTED
Endo International plc
ENDP
$5.74M 0.64%
126,215
– –
IDXX icon
40
Idexx Laboratories
IDXX
$44.1B
$5.61M 0.62%
112,530
– –
MDVN
41
DELISTED
MEDIVATION, INC.
MDVN
$5.53M 0.61%
184,400
-228,478
-55% -$6.52M
SGNT
42
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$5.51M 0.61%
270,031
– –
ARAY icon
43
Accuray
ARAY
$33.9M
$5.41M 0.6%
731,943
– –
BAX icon
44
Baxter International
BAX
$13.8B
$5.1M 0.57%
143,000
– –
AUXL
45
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$4.56M 0.51%
250,020
+122,500
+96% +$2.21M
AVNR
46
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$4.07M 0.45%
+960,000
New +$4.55M
ACOR
47
DELISTED
Acorda Therapeutics
ACOR
$3.87M 0.43%
941
– –
MACK
48
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$3.84M 0.43%
128,295
+59,966
+88% +$2.1M
ELN
49
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
$3.78M 0.42%
242,500
– –
IPCI
50
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$3.4M 0.38%
173,500
– –
1
2
3

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Tekla Capital Management held 69 positions worth $899M, up 22% from $735M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Tekla Capital Management's Q3 2013 filing shows 9 new, 12 increased, 10 reduced and 6 closed positions. Its largest new stake was iShares Biotechnology ETF: 251,820 shares worth $17.6M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $16.4M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 84% a quarter earlier, followed by Financials.

  • Tekla Capital Management's largest Q3 2013 buy was iShares Biotechnology ETF: 251,820 shares worth $17.6M.
  • Tekla Capital Management added most to Amgen in Q3 2013, an estimated $23M increase.
  • Tekla Capital Management's biggest Q3 2013 reduction was ONYX PHARMACEUTICALS INC, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Immunogen Inc in Q3 2013, selling an estimated $6.53M.
  • Tekla Capital Management's ten largest holdings make up 55% of its $899M portfolio in Q3 2013.
  • Tekla Capital Management opened 9 new positions and closed 6 in Q3 2013.
  • Tekla Capital Management's portfolio value rose 22% quarter-over-quarter to $899M.

Based on Tekla Capital Management's 13F filing for Q3 2013, filed 30 Oct 2013.